Page 112 - Read Online

Devarakonda et al. Impact of insurance on overall survival

literature. Cancer Metastasis Rev 2003;22:87-93. ED, Biritwum RB, Tettey Y, Adjei AA, Larson DR, Dispenzieri A,
3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Melton LJ 3rd, Goldin LR, McMaster ML, Caporaso NE, Rajkumar
Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, SV. Prevalence of monoclonal gammopathy of undetermined
Rajkumar SV. Monoclonal gammopathy of undetermined significance significance among men in Ghana. Mayo Clin Proc 2007;82:1468-73.
(MGUS) consistently precedes multiple myeloma: a prospective 13. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF,
study. Blood 2009;113:5412-7. Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence
4. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal of monoclonal gammopathy of undetermined significance. N Engl J
gammopathy precedes multiple myeloma in most patients. Blood Med 2006;354:1362-9.
2009;113;5418-22. 14. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris
5. Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody D, Fears TR, Hoover RN, Linet MS. Risk of monoclonal gammopathy
S, Korde N, Björkholm M, Landgren O, Kristinsson SY. The role of undetermined significance (MGUS) and subsequent multiple
of diagnosis and clinical follow-up of monoclonal gammopathy of myeloma among African American and white veterans in the United
undetermined significance on survival in multiple myeloma. JAMA States. Blood 2006;107:904-6.
Oncol 2015;1:168-74. 15. Munker R, Shi R, Nair B, Devarakonda S, Cotelingam JD, McLarty J,
6. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of Mills GM, Glass J. The Shreveport myeloma experience: survival, risk
underexplored significance. Blood 2016;128:2599-606. factors and other malignancies in the age of stem cell transplantation.
7. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Acta Hematol 2016;135:146-55.
Kristinsson SY, McGlynn KA, Landgren O. Racial disparities in 16. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR,
incidence and outcome in multiple myeloma: a population-based Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR,
study. Blood 2010;116:5501-6. Kyle RA, Gertz MA. Improved survival in multiple myeloma and the
8. Landgren O, Weiss B. Patterns of monoclonal gammopathy of impact of novel therapies. Blood 2008;111:2516-20.
undetermined significance and multiple myeloma in various ethnic/ 17. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between
racial groups: support for genetic factors in pathogenesis. Leukemia health insurance coverage and clinical outcomes among women with
2009;23:1691-7. breast cancer. N Engl J Med 1993;329:326-31.
9. Walker B, Figgs L, Zahm S. Differences in cancer incidence, mortality, 18. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK,
and survival between African Americans and whites. Environ Health Pinson CW. Health insurance status affects staging and influences
Perspect 1995;8:275-81. treatment strategies in patients with hepatocellular carcinoma. Ann
10. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron Surg Oncol 2010;17:3104-11.
W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, 19. Kent EE, Sender LS, Largent JA, Anton-Culver H. Leukemia survival
Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards in children, adolescents and young adults: influence of socioeconomic
BK, editors. SEER Cancer Statistics Review 1975-2007. Bethesda, status and other demographic factors. Cancer Causes Control
MD: National Cancer Institute; 2010. Available from: http://seer. 2009;20:1409-20.
cancer.gov/csr/1975_2007/</csr/1975_2007/>, based on November 20. Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed
2009 SEER data submission, posted to the SEER web site. J, Faiman B, Hussein M. The role of race, socioeconomic status, and
11. Schaar CG, le Cessie S, Snijder S, Franck PF, Wijermans PW, Ong C, distance traveled on the outcome of African-American patients with
Kluin-Nelemans H. Long-term follow-up of a population based cohort multiple myeloma. Haematologica 2006;91:1410-3.
with monoclonal proteinaemia. Br J Haematol 2009;144:176-84. 21. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment.
12. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah Mayo Clin Proc 2005;80:1371-82.

104 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ June 9, 2017